Theravance Biopharma, Inc.

Theravance Biopharma, Inc. is a biopharmaceutical company focused on developing and commercializing medicines. The company leverages its expertise to develop medicines, including the U.S. Food and Drug Administration (FDA) approved YUPELRI (revefenacin) inhalation solution. YUPELRI is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). On March 3, 2026, the company announced that its ampreloxetine Phase 3 clinical study (CYPRESS), which was in development for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy, did not meet its primary endpoint in the Orthostatic Hypotension Symptom Assessment composite score. Consequently, the ampreloxetine program is being wound down. A Strategic Review Committee, formed in 2024, is accelerating its review of alternatives to maximize shareholder value, working with Lazard, its independent financial advisor. This review includes evaluating a broad range of value-maximizing and tax-efficient alternatives, such as a potential sale of the company. The company will complete additional analyses of the CYPRESS dataset and Phase 3 program to assess if the data warrants further regulatory discussion.